You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
佰仁醫療(688198.SH):上半年淨利升2.96%至3318.40萬元
格隆匯 08-19 17:35

格隆匯8月19日丨佰仁醫療(688198.SH)披露2020年半年度報告,報告期內,公司實現營業收入6687.91萬元,同比下降3.25%;實現歸屬於母公司所有者的淨利潤3318.40萬元,同比增長2.96%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤2518.50萬元,同比下降19.06%。

報告期內,公司營銷團隊進一步擴大到54人,公司聚焦重點產品,新設立胸普外銷售中心,負責外科生物補片在胸外科與疝外科領域的市場開發;擴充成人心外銷售中心、神經外科銷售中心成員,新增的營銷團隊成員多為行業內資深人才,具備豐富的行業經驗及獨立開發市場、拓展渠道的能力;同時,營銷中心下屬的市場部、渠道管理部、招投標部人員也得到一定程度的擴大,並在進一步吸納人才,以更好地配合公司營銷策略的實施,實現業績持續增長。

報告期內,面對新冠肺炎疫情的影響,公司加強了重點產品的線上學術推廣活動及線上銷售培訓,並在二季度有計劃地開展了一批針對重點目標醫院的小型線下學術研討會;針對生物瓣膜產品,結合線上線下學術推廣與溝通,有效傳播了最新發表在核心學術期刊上的佰仁思牛心包生物瓣14年隨訪結果,獲得較好效果,推動了產品進入重點醫院使用的進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account